Download Cavendish NanoTherapeutics (CNT)

1
Cavendish NanoTherapeutics
…fighting cancer with smart magnetic nano-bullets
Medical systems aimed at increasing the efficacy of cancer treatment
Dr Thanos Mitrelias
Founding CEO
Cambridge, UK
C A V E N D I S H
NanoTherapeutics
2
Introducing CNT…
Go to market
Product:
MagTherm®
Spin off the
Physics Dept,
University of
Cambridge, UK
State of the art
production
facilities
ISO 9001 and
13485 certified
Awarded
Technology
Strategy Board
(TSB) grant
£380k
C A V E N D I S H
NanoTherapeutics
3
Problem Statement
 Cancer affects 1 in 4 individuals and is a major cause of morbidity and mortality
and high burden to health care systems: Over 1.5 million new diagnoses in US
alone annually. Overall cost to health care system over $100 billion
 Standard treatment methods have serious side effects and limitations
• High systemic toxicity. Healthy tissues affected
• Limit dose of drug/treatment
• Drug resistance
 Breast cancer is the 2nd most prevalent cancer in the world
 Hyperthermia is a recognised modality in modern cancer treatment, however, it is
both promising and problematic
 Heat shock proteins inhibit treatment
 Side effects, cardiotoxicity
 Initiation of drug resistance
C A V E N D I S H
NanoTherapeutics
4
MagTherm® - key benefits
 Go to market product : MagTherm®
MagTherm
– Best
• Adjunct treatment,
easily integrated
with
Partner with Chemotherapy
current practice
•
£130,000/unit
• Non invasive treatment
• 30 min – 1 hour
•
Non-invasive treatment 15
chemotherapy by 20%
• Easy to integrate
• 30 mins - 1hour
•
20% increase of
chemotherapy efficacy
• Competitive priced
• Upgradable to
Volume of tumor ( cm3 )
• Increasing the efficacy
of
• Portable,
self-contained
Control
10
Chemotherapy
5
Chemotherapy + MagThermTM
NanoMagTherm®
2nd generation product that uses
nanoparticles for increased targeting
0
10
12
14
16
18
20
Time after tumor transplantation (Day)
C A V E N D I S H
NanoTherapeutics
22
5
MagTherm® - Science and Technology
• Improve performance of generic chemotherapy in solid tumors,
through multiple mechanisms of action:
• Focused, mild hyperthermia increases vascularization, blood flow and
metabolic activity in tumor cells, increasing opportunity for cytotoxic
drugs to kill cancer cells
Before irradiation
After irradiation
• Magnetic fields concentrate free radicals and extend their lifetime in the
tumor area, leading to oxidative stress on tumor cells (patent filed).
C A V E N D I S H
NanoTherapeutics
6
Clinical Data
Before irradiation
with MagTherm®
After irradiation
with MagTherm®
Temperature increase not
more than 3.6º C
32,3
◦С
35,9
◦С
32,3
◦С
35,9
◦С
C A V E N D I S H
NanoTherapeutics
Locally Advanced Breast Cancer
Patients (n)
(1)
35
30
25
20
15
10
5
0
Main group: MagTherm® +
chemo: 65 patients
Control group: chemotherapy
only: 63 patients
Complete
regression
Partial
regression
Stable
Progression
Conclusion: 14-16% more
patients were in partial
regression/stable condition
(2) Evaluation of Axillary Lymph Nodes (LN)
Main group (chemotherapy + MagTherm®): 23 patients
Control group (chemotherapy only): 88 patients
Index
Average of LN
regression after
treatment (%)
Main group
37,57 ± 13,06
Control group
19,84 ± 7,13
C A V E N D I S H
NanoTherapeutics
Chemotherapy scheme (known as
FAC):
 5-Fluororacil 500 mg/m2
 doxorubicin 50 mg/m2
7
 cyclophamide
500 mg/m2
8
Patients (n)
(3)
10
9
8
7
6
5
4
3
2
1
0
Breast Cancer and multiple Liver metastases
 46 patients in total, mean age 55 yrs
 25 patients chemotherapy with MagTherm®
 21 control group-only chemotherapy
Main group
Control group
Main group: chemotherapy + MagTherm®
Control group: chemotherapy only
Partial
Progression
Stable
Progression
Conclusion: 17% more patients were in stable condition when irradiated with
the MagTherm® and in 20% less patients irradiated diseased progressed
C A V E N D I S H
NanoTherapeutics
9
Second Generation Product: NanoMagTherm®
Animals with Guerin carcinoma: EM + NanoComplexes
 NanoMagTherm®: MagTherm® combined with proprietary NanoComplexes injected into tumours
 NanoComplexes comprise magnetic nanoparticles and anticancer drugs (eg doxorubicin).
Synthesised with especially developed, proprietary method to enhance physicochemical properties
(a)
(b)
(c)
MR images of a rat with Guerin carcinoma:
(a) control, tumour 13 days after transplantationMRM
(b) same tumour 15 mins after injection of nanocomplexes
(c) same tumor 21 days after transplantation: note that the nanocomplexes are still in place
C A V E N D I S H
NanoTherapeutics
10
1
50
45
1
40
35
2
30
2
25
33
20
15
4
10
5
0
9
Time after tumor transplantation, days
11
13
15
Time after tumor transplantation, days
Volume of tumour, cm3
Volume of tumor, сm3
NanoMagTherm®
Animals with Guerin carcinoma: EM + NanoComplexes
17
Time after tumour transplantation, days
60
50
40
30
20
10
0
1
2
3
Survival rate
Survival rate
1 – without Doxorubicin (DOXO) and electromagnetic irradiation (control);
2 - DOXO intravenously
3 – nanocomplexes intravenously
4 – nanocomplexes intravenously + non-homogeneous EM irradiation: NanoMagTherm®
C A V E N D I S H
NanoTherapeutics
4
Team
Founding CEO: Thanos Mitrelias, PhD. 16 years of scientific and
entrepreneurial activity. Founding CEO of Cambridge BioMagnetics. Interim
CEO of Tarabios, spin off Koc University. Raised and managed more than $5.5
million. Engaged in translational research and numerous international projects in
academia, industry and education (S. America, ME, India, China). PhD Nat Sci
Univ. Cambridge. MSc Mat Science.
Founding Director: Prof. Marina Tselepi, PhD. Experienced academic,
international project management. >40 international papers in magnetism and
biomagnetism. Attracted funding from European Union. Affiliated with
Cavendish Lab since 1994, Univ. of Cambridge.
Founding Director: Prof. Valerie Orel, National Cancer Institute, Kiev,
Ukraine 30+ years of expertise in medical engineering. Head of group.
Scientific Collaborator: Prof. Crispin Barnes, PhD. Head of TFM group,
Cavendish Laboratory.
C A V E N D I S H
NanoTherapeutics
11
12
Products + Timeline
 Go to market Flagship Product: MagTherm®
adjunct, non invasive treatment, increasing
the efficacy of chemotherapy
 Initial market segment: Breast cancer
 Expand to other cancer types
 2nd product: MagTherm® + state of the art ultrasound system
(Ultima PA) to enhance diagnosis and guide treatment
 3nd product (2+ years) : NanoMagTherm® to enhance targeting ability
of MagTherm™ with nanocomplexes comprised of nanoparticles and drug
C A V E N D I S H
NanoTherapeutics
Objectives
13
Plan for next 12 to 24 months
• Main goal: obtain CE marking MagTherm®
• Partnerships with clinicians, medical professionals to help us to understand
better our preliminary clinical data and plan clinical trials
• Install a number of MagTherm® units in selected hospitals/clinics
• Clinical Trials (Phase III?) of MagTherm®
• Regulatory approval in Europe and beyond
• R&D collaborative partnerships for NanoMagTherm® commercialisation
• Proposals to various national and international funding bodies
• Utilise strong links we have with Thin Film Magnetism group at
Cavendish Labs
C A V E N D I S H
NanoTherapeutics
14
Contact Information
Dr Thanos Mitrelias
[email protected]
Tel: +44 774 7793441
Dr Marina Tselepi
[email protected]
Tel: +44 778 9951594
Cavendish NanoTherapeutics Ltd. Registered in England and Wales No 7706398
CPC1, Capital Park, Fulbourn, Cambridge, CB21 5XE, United Kingdom
Medical Oncologists at National Cancer Institute, Kiev
Prof Ivan Smolanka: Head of Department of Breast Cancer and Reconstructive Surgery
Dr Natali Tsip: Trophoblastic cancer
Dr Anton Loboda, Dr Irina Dosenko, Prof Ivan Smolanka: Breast cancer locally
advanced
Dr Lubov Syvak, Dr Mishel Klimanov: Liver cancer
Dr Sergei I. Korovin: Head of Department of Skin and Soft Tissues Cancer
C A V E N D I S H
NanoTherapeutics
15
NanoComplex: Doxorubicin and magnetic nanoparticles
Elements, %
Nanocomplex
Сonventional
doxorubicin
Doxorubicin
(mechano-magnetochemically treated
Fe3O4+KCl (without
influence)
Fe
–
–
O
33,63
33,63
Сl
K
–
0,83
0,83
-
g-factor
Saturation
Concentration
magnetic
of free-radical
moment,
spin, mg-1
emu/g
1,97
5·1017
2,003
8·1017
2,005
4·1017
2.003
1018
– 0,200
Diamagnetic
Paramagnetic
+ 0, 06836
70,47
27,15
1,12
1,27
2,38
4·1019
54,006
Fe3O4+KCl+doxorubicin
(mechano-chemically
13,83
synthesized )
76,65
7,29
1,00
2,31
3·1020
6,7767
. Soft
Fe3O4+KCl+doxorubicin
(mechano-magnetochemically synthesized ) 15,12
ferromagnetic
32,24
2,15
0,38
2,64
C A V E N D I S H
NanoTherapeutics
1021
11,781
15
16
Plan & Use of Proceeds
• About $500k invested in the company so far
• Seeking $2 million for 20% equity (pre-money)
Year 1
Year 2
• Manufacture 7 units
• CE Certification
• Market and Sell MagTherm
• Clinical trials for 2nd generation
• Revenue sharing partnerships
• Clinical Trials
• R&D: 2nd generation system
• Plan for CNT-China – 12 to 18 months
• Install min 7 MagTherm® units in selected hospitals/clinics
• Establish partnerships; alliances with regional agencies
• Clinical Trials (Phase III) of MagTherm®
• Registration with MoH in China and regulatory approval
• R&D collaborative partnerships for NanoMagTherm® commercialisation
C A V E N D I S H
NanoTherapeutics
17
Revenue Generating Strategies
 Each
system $200k to $500k
 One system can treat minimum 1000 patients annually
 Revenue sharing partnerships; each system could generate $150k to >$400k
Financial Projections
USD $ '000
Revenues
Production cost
Gross Profit
Year 1
EBITDA
Year 3
Year 4
Year 5
0
3,692
11,882
38,377
87,572
286
787
2,242
7,155
16,759
-286
2,905
9,640
31,222
70,813
79%
81%
81%
81%
1,972
2,414
5,748
7,510
8,459
-2,258
491
3,892
23,713
62,355
Gross margin
Total Operating
Expenses
Year 2
C A V E N D I S H
NanoTherapeutics
18
Change of Thermal Pattern of Tumour Surface
Control
Quasi-uniform
EM field
Non-homogeneous EM field –
MagTherm™: Increased
localization of heating
1: Control
2: With Doxorubicin
3: As 2 + homogeneous EM field
4: As 2+ non-homogeneous EM field
1: Quasi uniform field
2: Non-homogeneous field
Note the mild hyperthermia,
i.e. small increase of
temperature
C A V E N D I S H
NanoTherapeutics
19
Hyperthermia Market for Breast Cancer ( China )
Hyperthermia Market for Breast Cancer (China)
Market Size (m£)
Competitor analysis
Oncologist interview
1220
933
Unmet need of current
Hyperthermia Technology
669
415
• Damage to normal tissue
• High discomfort level
189
2010
2015
2020
2025
2030
C A V E N D I S H
NanoTherapeutics